Dr Reddy stock trades at INR 1,211.20 before October 23 results

Published on 10/14/2026 at 11:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dr Reddy sets results for October 23, 2026. Dr Reddy stock trades at INR 1,211.20 on BSE, down 2.29 percent versus INR 1,239.65.

Results date and valuation

Dr Reddy's Laboratories will announce results for the quarter and half-year ended September 30, 2026, on October 23, 2026.
Dr Reddy stock was trading at INR 1,211.20 on October 14, 2026, down 2.29 percent versus INR 1,239.65.
The company had a market capitalization of INR 1.0 trillion and a P/E ratio of 30.49 on October 14, 2026.

Dr Reddy, INE089A01023, Illustration mit AI erstellt.

Dr Reddy stock (INE089A01023) was trading at INR 1,211.20 on BSE on October 14, 2026 at 3:07 p.m. IST, down 2.29 percent versus the previous close of INR 1,239.65. The next major reference point is the company's scheduled results announcement on October 23, 2026.

October 23 results date

StockTitan reported that Dr. Reddy's Laboratories will announce results for the quarter and six months ended September 30, 2026, on October 23, 2026, after a board meeting. The company also scheduled an earnings call for 7:30 p.m. IST that day.

That calendar date gives the stock a defined near-term event window. The September quarter and first-half results will provide the next fresh operating data after the April-June 2026 figures cited in recent coverage.

Price position on BSE

The BSE quote stood at INR 1,211.20 at 3:07 p.m. IST on October 14, 2026, compared with INR 1,239.65 at the previous close. The resulting decline was 2.29 percent, while reported volume was 43,450 shares against an average of 98,725 shares.

The 52-week BSE range ran from INR 1,025.90 to INR 1,414.40. The latest price was INR 203.20 above the low and INR 203.20 below the high only as an absolute midpoint comparison; the range itself places the shares 14.37 percent below the 52-week high.

Valuation and analyst view

Dr Reddy's Laboratories had a market capitalization of INR 1.0 trillion and a P/E ratio of 30.49 on October 14, 2026. Its trailing dividend yield was 0.01 percent, keeping valuation and earnings delivery central to the October results reaction.

According to Business Insider on October 12, 2026, BNP Paribas upgraded Dr. Reddy's to Outperform from Neutral and set a USD 14.80 price target.

Comparison with peers

Dr Reddy: minus 2.29 percent, P/E 30.49, market capitalization INR 1.0 trillion.

Sun Pharma (BSE, INR): minus 1.88 percent, P/E 34.55, market capitalization INR 4.2 trillion.

Cipla (BSE, INR): minus 1.80 percent, P/E 31.44, market capitalization INR 1.1 trillion.

Trading ahead of results

Dr Reddy's share-price decline on October 14, 2026 came with volume below its average, while the two named peers also traded lower. The October 23 reporting date therefore supplies the next measurable test for earnings expectations and valuation.